Dopamine Agonist Drugs Need Compulsion Warning: Group

By Adam Lidgett (July 1, 2016, 7:23 PM EDT) -- A Washington, D.C.-based consumer advocacy group has sent a petition to the U.S. Food and Drug Administration saying that dopamine agonist drugs should have a black-box warning about side effects that can cause compulsive behavior, such as extreme desires for sex, eating, shopping and gambling.

In its petition sent to FDA Commissioner Robert Califf on Wednesday, Public Citizen said there are serious compulsive reactions to dopamine agonist drugs, such as the antipsychotic drug Abilify, which can be reduced if a warning label is put on the drugs. Public Citizen called on the FDA to require information be given to doctors and...

Stay ahead of the curve

In the legal profession, information is the key to success. You have to know what’s happening with clients, competitors, practice areas, and industries. Law360 provides the intelligence you need to remain an expert and beat the competition.


  • Access to case data within articles (numbers, filings, courts, nature of suit, and more.)
  • Access to attached documents such as briefs, petitions, complaints, decisions, motions, etc.
  • Create custom alerts for specific article and case topics and so much more!

TRY LAW360 FREE FOR SEVEN DAYS

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!